• by Les Luchter , Yesterday

Avoiding the hoopla of the 4/20 cannabis “holiday,” Kazmira Therapeutics -- which in January debuted the only compounding pharmacy in the U.S. dedicated to medical-grade CBD -- waited until 4/21 to launch 1Cannabis, a online educational platform serving both healthcare providers (HCPs) and patients.

The pharma company, which currently serves Colorado, plans to launch telemedicine services for state residents in May, and to expand into 20 other states by year’s end, including Arizona, Florida, Texas, and Utah.

Kazmira’s goal is to “move CBD from an over-the-counter product to evidence-based, pharmacy-dispensed medicine,” Co-Founder/Co-CEO Dr. Priyanka Sharma said in a statement when the pharmacy launched.

In making Tuesday’s announcement, Sharma noted how HCPs have “been missing the clinical infrastructure -- licensed providers, compounding pharmacies, and therapeutic dosing -- that patients deserve. The education gap for clinicians has been a critical barrier.”

Sharma explained the impact of ultra pure CBD has been studied on a variety of health conditions, including pain management, anxiety disorders, and substance abuse disorders. Prescription-only CBD could make a difference for patients who may not have responded well to other treatments on the market.

1Cannabis focuses largely on the differences between medical cannabis and retail CBD.

The platform currently features two free programs: a 30-minute video for patients and a 90-minute one for HCPs.

“Learn how to talk about CBD with your healthcare provider using clear, informed language,” patients are told, “so you can ask better questions and feel more involved in your care.”

On the other side, HCPs can “gain the confidence to engage—rather than avoid—CBD discussions with patients,” Kazmira says, “using clear language grounded in physiology, evidence, and clinical judgment instead of stigma or uncertainty.”

Kazmira’s latest move comes after the launch earlier this month by the U.S. Centers for Medicare & Medicaid Services (CMS) of a pilot Substance Access Beneficiary Engagement Incentive (BEI) for certain CBD medical products.

“As emerging CMS-aligned pathways begin to take shape,” Kazmira stated, “1Cannabis has established the clinical and operational protocols required to support implementation within compliant care models. These include structured patient intake, physician-guided dosing protocols, documentation workflows, and longitudinal monitoring aligned with program integrity expectations.”